Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss IndustryThe Motley Fool • 12/21/23
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.The Motley Fool • 12/21/23
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?Market Watch • 12/20/23
Novo Nordisk owner channels some of Wegovy windfall into respiratory diseasesProactive Investors • 12/18/23
Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold OnlineForbes • 12/18/23
Exclusive: IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales -sourceReuters • 12/18/23
Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.The Motley Fool • 12/14/23